June 10, 2020 / 3:23 PM / a month ago

BRIEF-Johnson & Johnson Announces Acceleration Of Its Covid-19 Vaccine Candidate

June 10 (Reuters) - Johnson & Johnson:

* JOHNSON & JOHNSON ANNOUNCES ACCELERATION OF ITS COVID-19 VACCINE CANDIDATE; PHASE 1/2A CLINICAL TRIAL TO BEGIN IN SECOND HALF OF JULY

* J&J - PHASE 1/2A STUDY OF INVESTIGATIONAL SARS-COV-2 VACCINE, AD26.COV2-S, WILL TAKE PLACE IN U.S. AND BELGIUM

* J&J - PHASE 1/2A FIRST-IN-HUMAN CLINICAL TRIAL OF AD26.COV2-S IS NOW EXPECTED TO COMMENCE IN SECOND HALF OF JULY

* J&J - IN DISCUSSIONS WITH NIAID WITH OBJECTIVE TO START PHASE 3 AD26.COV2-S, RECOMBINANT, CLINICAL TRIAL AHEAD OF ITS ORIGINAL SCHEDULE

* J&J - IN DISCUSSIONS TO START PHASE 3 SARS-COV-2 VACCINE TRIAL AHEAD OF SCHEDULE, PENDING PHASE 1 STUDIES OUTCOME, REGULATOR APPROVAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below